Krebs Biochemicals Q1 FY27 Results: Revenue Rs 6 Cr, PAT Rs 2.00 Cr and Key Highlights

Krebs Biochemicals Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. Krebs Biochemicals Q1 FY27 results show revenue grew +27.42% year-on-year to Rs 6 Cr from Rs 5 Cr in Q1 FY26, reflecting sustained demand in the Chemicals segment.

Operating profit improved +79.36% YoY to Rs -1 Cr from Rs -3 Cr, indicating stronger operational efficiency. The company reported a net loss of Rs 2.00 Cr in Q1 FY27, narrowing from a loss of Rs 5.00 Cr in Q1 FY26, indicating a gradual recovery trajectory. The quarterly numbers offer a detailed picture of how the company is navigating the current chemicals environment.

Click Here – Get Free Investment Predictions

Krebs Biochemicals Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Krebs Biochemicals Revenue	6	5	+27.42%
Operating Profit	-1	-3	+79.36%
Net Profit (PAT)	-2.00	-5.00	+53.33%
Reporting Basis	Standalone

Krebs Biochemicals Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Krebs Biochemicals Q1 FY27 results reflect strong fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 6 Cr for the April to June 2026 quarter.

Operating profit stood at Rs -1 Cr, expanding +79.36% YoY. Margin improvement signals better cost absorption and product mix optimisation.

The net loss of Rs 2.00 Cr in Krebs Biochemicals Q1 FY27 results indicates that the turnaround is still in progress. Investors monitoring Krebs Biochemicals Q1 FY27 results will note this as a key milestone for FY27 tracking.

Key Business Factors in Krebs Biochemicals Q1 FY27 Results

Revenue Growth Momentum in the Chemicals Segment

Krebs Biochemicals Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +27.42% YoY to Rs 6 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.

Operating Margin Expansion Signals Efficiency Gains

Operating profit in Krebs Biochemicals Q1 FY27 results rose +79.36% YoY to Rs -1 Cr. This reflects tighter cost control, better product mix, and operating leverage as the company scales volumes in core business lines.

Net Loss and Path Toward Profitability

Krebs Biochemicals Q1 FY27 results reflect a net loss of Rs 2.00 Cr. Management has outlined a roadmap to profitability through operational restructuring, debt reduction, and revenue scaling in higher-margin product lines.

Dividend Details

No dividend was announced along with Krebs Biochemicals Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.

FY27 Outlook for Krebs Biochemicals

Krebs Biochemicals is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the Chemicals business with a focus on margin improvement and market share consolidation. Investors tracking Krebs Biochemicals Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.

Krebs Biochemicals Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Krebs Biochemicals live price and get daily stock recommendations.

Krebs Biochemicals shares were trading higher at Rs 54.51 (+0.72%) on August 6, 2026, following the declaration of Krebs Biochemicals Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 54.51 on the results date, with a 52-week range reflecting the broader market sentiment toward the chemicals sector.

Key Risks for Krebs Biochemicals

Sector-Specific Headwinds

Feedstock price volatility and Chinese competition in commodity chemicals remain risks.

Valuation and Earnings Risk

Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.

Operational and Financial Risk

Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.

Conclusion

Krebs Biochemicals Q1 FY27 results reflect near-term operational challenges with revenue at Rs 6 Cr and a net loss of Rs 2.00 Cr on a Standalone basis. The management's ability to execute its recovery plan will determine the stock's re-rating potential. Investors are advised to monitor quarterly progress before making investment decisions.

Frequently Asked Questions on Krebs Biochemicals Q1 FY27 Results

When were Krebs Biochemicals Q1 FY27 results declared?

Ans. Krebs Biochemicals Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.

What was Krebs Biochemicals revenue in Q1 FY27?

Ans. Krebs Biochemicals Q1 FY27 results show revenue of Rs 6 Cr, +27.42% compared to Rs 5 Cr in Q1 FY26.

What was Krebs Biochemicals PAT in Q1 FY27?

Ans. Net loss in Krebs Biochemicals Q1 FY27 results was Rs 2.00 Cr, +53.33% year-on-year.

Did Krebs Biochemicals declare a dividend in Q1 FY27?

Ans. No dividend was declared alongside Krebs Biochemicals Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.

What is the FY27 outlook for Krebs Biochemicals?

Ans. Krebs Biochemicals management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.

How did the Krebs Biochemicals stock react to Q1 FY27 results?

Ans. Krebs Biochemicals shares were trading higher at Rs 54.51 (+0.72%) on August 6, 2026, following the Krebs Biochemicals Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.